EXACOS EG Population

Launched by ASTRAZENECA · May 13, 2025

Keywords

ClinConnect Summary

The EXACOS EG Population trial is studying how acute exacerbations (worsening symptoms) of chronic obstructive pulmonary disease (COPD) affect patients in Egypt. COPD is a long-term lung disease that makes it hard to breathe, and many people experience sudden worsening of their symptoms, which can lead to more serious health problems. The trial aims to gather more information about how often these episodes happen and how they impact patients' lives and health care needs in Egypt, where COPD is a significant health issue.

To participate in this trial, you need to be over 40 years old and have been diagnosed with COPD for at least three years, with records showing your lung function and treatment history. Participants will be asked to sign a consent form and will help researchers understand more about COPD and its effects in Egypt. This study is not yet recruiting participants, but it is an important step in learning how to better manage and treat COPD in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. are over the age of 40 years old;
• • 2. have had an investigator-confirmed diagnosis of COPD of at least 3 years prior to the index date;
• • 3. have COPD-related data recorded in medical records for at least 3 years prior to the index date, including spirometry (at least one FEV1 measurement) and medication data;
• • 4. have signed a written Informed Consent Form
• Exclusion Criteria:
• • 1. have a diagnosis of bronchiectasis, sarcoidosis, Interstitial Lung Diseases, or Idiopathic pulmonary fibrosis. This is because differentiating deteriorations in symptoms/exacerbations in these individuals at attributing them to COPD is impossible.